Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22477390 | 0.85 | ALOX15 (0.42) | ALOX15NOS3NOS1NOS2CYP2D6 | |
| SCHEMBL22477429 | 0.83 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2 | |
| SCHEMBL26147483 | 0.79 | CYP2D6 (0.33) | CYP2D6SMN1; SMN2 | |
| SCHEMBL4546598 | 0.79 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2 | |
| SCHEMBL22268039 | 0.77 | NOS3 (0.45) | NOS3NOS1NOS2CCR5 | |
| SCHEMBL23135139 | 0.74 | CYP2D6 (0.41) | ALOX15CYP2D6SMN1; SMN2 | |
| SCHEMBL22477421 | 0.74 | CYP2D6 (0.41) | ALOX15CYP2D6SMN1; SMN2 | |
| SCHEMBL22477401 | 0.74 | CYP2D6 (0.41) | ALOX15CYP2D6SMN1; SMN2 | |
| SCHEMBL22520121 | 0.74 | TSHR (0.30) | — | |
| SCHEMBL23135133 | 0.73 | CYP2D6 (0.40) | CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3715343-A1 | DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2020-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | ALK, BRAF, MUSK | ALOX15 2116/4885NOS3 4185/4885NOS1 3033/4885 |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | ALK, BRAF, MUSK | ALOX15 1717/4885NOS3 4315/4885NOS1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.